VTAK

Company Overview — What Does Catheter Precision, Inc. Do?

Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina. Catheter Precision, Inc. (VTAK) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO David A. Jenkins and employs approximately 14 people. With a market capitalization of $2M, VTAK is one of the notable companies in the Healthcare sector.

Catheter Precision, Inc. (VTAK) Stock Rating — Avoid (April 2026)

As of April 2026, Catheter Precision, Inc. receives a Avoid rating with a composite score of 28.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.VTAK ranks #3,970 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Catheter Precision, Inc. ranks #685 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VTAK Stock Price and 52-Week Range

Catheter Precision, Inc. (VTAK) currently trades at $1.19. The stock lost $0.02 (1.7%) in the most recent trading session. The 52-week high for VTAK is $4.31, which means the stock is currently trading -72.4% from its annual peak. The 52-week low is $0.15, putting the stock 715.1% above its annual trough. Recent trading volume was 287K shares, suggesting relatively thin trading activity.

Is VTAK Overvalued or Undervalued? — Valuation Analysis

Catheter Precision, Inc. (VTAK) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.31x, versus the sector average of 2.75x. The price-to-sales ratio is 3.05x, compared to 1.66x for the average Healthcare stock.

At current multiples, Catheter Precision, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Catheter Precision, Inc. Profitability — ROE, Margins, and Quality Score

Catheter Precision, Inc. (VTAK) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -240.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -100.7% versus the sector average of -33.1%.

On a margin basis, Catheter Precision, Inc. reports gross margins of 91.8%, compared to 71.5% for the sector. The operating margin is -2256.3% (sector: -66.1%). Net profit margin stands at -2683.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 143.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VTAK Debt, Balance Sheet, and Financial Health

Catheter Precision, Inc. has a debt-to-equity ratio of 46.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.10x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $3M. Cash and equivalents stand at $1M.

VTAK has a beta of -0.85, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Catheter Precision, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Catheter Precision, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Catheter Precision, Inc. reported revenue of $677,000 and earnings per share (EPS) of $-15.90. Net income for the quarter was $-16M. Gross margin was 91.8%. Operating income came in at $-14M.

In FY 2025, Catheter Precision, Inc. reported revenue of $819,000 and earnings per share (EPS) of $-15.90. Net income for the quarter was $-18M. Gross margin was 92.3%. Revenue grew 95.0% year-over-year compared to FY 2024. Operating income came in at $-21M.

In Q3 2025, Catheter Precision, Inc. reported revenue of $226,000 and earnings per share (EPS) of $-1.70. Net income for the quarter was $-2M. Gross margin was 92.0%. Revenue grew 135.4% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, Catheter Precision, Inc. reported revenue of $212,000 and earnings per share (EPS) of $-0.38. Net income for the quarter was $-5M. Gross margin was 93.4%. Revenue grew 128.0% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, Catheter Precision, Inc. has demonstrated a growth trajectory, with revenue expanding from $93,000 to $677,000. Investors analyzing VTAK stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VTAK Dividend Yield and Income Analysis

Catheter Precision, Inc. (VTAK) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VTAK Momentum and Technical Analysis Profile

Catheter Precision, Inc. (VTAK) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

VTAK vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Catheter Precision, Inc. (VTAK) ranks #685 out of 838 stocks based on the Blank Capital composite score. This places VTAK in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VTAK against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VTAK vs S&P 500 (SPY) comparison to assess how Catheter Precision, Inc. stacks up against the broader market across all factor dimensions.

VTAK Next Earnings Date

No upcoming earnings date has been announced for Catheter Precision, Inc. (VTAK) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VTAK? — Investment Thesis Summary

The quantitative profile for Catheter Precision, Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. High volatility (stability score 30/100) increases portfolio risk.

In summary, Catheter Precision, Inc. (VTAK) earns a Avoid rating with a composite score of 28.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VTAK stock.

Related Resources for VTAK Investors

Explore more research and tools: VTAK vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VTAK head-to-head with peers: VTAK vs AZN, VTAK vs SLGL, VTAK vs VMD.